U.S., March 26 -- ClinicalTrials.gov registry received information related to the study (NCT07493122) titled 'Study of IMC-S118AI in Type 1 Diabetes' on March 19.
Brief Summary: This is a first-in-human (FIH) study designed to assess the safety, tolerability, and pharmacokinetic (PK) profile of IMC-S118AI in single-ascending dose (SAD) and multiple-ascending dose (MAD) regimens. This study will potentially also explore the effects of multiple-dosing regimens on preservation of beta-cell function in Stage 3 Type 1 diabetes.
Study Start Date: April, 2026
Study Type: INTERVENTIONAL
Condition:
Type 1 Diabetes
Type 1 Diabetes (T1D)
Diabetes Type 1
Intervention:
BIOLOGICAL: IMC-S118AI
IMC-S118AI solution for infusion/injection
Recruitmen...